Linking Antibody To Drug With ThioBridge® Conjugation Technology For Better ADCs

Antibody-drug conjugates (ADCs) have emerged as a promising therapeutic modality for targeted cancer treatment. However, first-generation ADC development has been hampered by limitations such as inconsistent drug-to-antibody ratios (DAR) and unstable linker chemistries. Abzena's ThioBridge® technology addresses these challenges by providing a novel approach that offers a more uniform DAR profile, enhanced linker stability, and improved pharmacokinetic properties.

ThioBridge® conjugation enables precise control over drug loading and attachment sites, resulting in a more uniform DAR distribution compared to traditional methods. Furthermore, ThioBridge® technology is compatible with diverse linker architectures and payload release mechanisms, allowing for the development of ADCs with optimized therapeutic profiles.

Learn how Abzena's ThioBridge® conjugation technology can provide a more uniform DAR profile, enhanced linker stability, and improved pharmacokinetic properties, paving the way for the development of more efficacious and well-defined ADCs for cancer therapy.